Study On The Change Of Immune Status In Patients With Advanced Tumor Treated With CIK

Objective: Observe different patients’ change of immune state and maintainance of immune function before and after treatment, Evaluate the effectiveness of CIK cell therapy in patients improve ment of immune function, in order to determine the patient’s condition and treatment and to provide guidance for clinicians to carry out a reasonable period CIK cell therapy offers in accordance with.Methods: 20 cases of patients with advanced cancer were chosen from Yantai C ity Tumor Hospital, who were in line with pathologic TNM stage Ⅲ stage and more, and receive continuous CIK cell treatment for at least two courses. Venous blood were collected at four time points CIK before treatment, after treatment 10 days, 30 days, 60 days. C hecked T lymphocytes grouping, NK cell and Treg cell percentage by flow cytometry, tested IL-2 and IFN-γ expression levels in serum by ELISA. There were 20 healthy persons(no autoimmune diseases and vital organ dysfunction) from health examination center in the separate control group. Compared the differences of immune parameters between cancer patients and normal controls, and the changes of immune parameters before and after treatment at different time points. Compared treatment groups combined radiotherapy and chemotherapy treatment, and simple changes in immune parameters, and disease remission after treatment group and the progress of the group changes in the immune parameters. Q uantitative data on each of the above samples were taken to compare two sample t test.Results: CD3 decreased in patients with advanced cancer(P <0.05). C D4, CD4 / CD8, NK cells, IL-2, IFN-γ levels dropped, but CD8, Treg cell levels increased. Compared with the control group, there was a significant difference(P <0.01). With CIK 10 days of treatment, IL-2, IFN-γ levels increased(P <0.05), and other indicators did not change significantly. With CIK 30 days of treatment, CD4 / CD8 ratio increased(P <0.05), significantly increased NK cell and IL-2, IFN-γ levels(P <0.01), CD8 levels decreased(P <0.05), decreased levels of Treg cells(P <0.01). With CIK therapy 60 days, Treg cell levels compared with 30 days increased, but there was not statistically significant. If NK cells, IL-2, IFN-γ levels than treatment for 30 days decreased, there was statistically significant(P <0.05). C hemoradiotherapy treatment group and CIK therapy alone in the treatment group at 30 days, all changes in immune parameters was no significant difference; after 60 days of treatment, the combined group of NK cells was significantly higher than group(P <0.05), Treg cell levels were significantly lower than alone treatment group(P <0.05). Remission 30 days after CIK cell treatment group underwent 60 days of CD4 / CD8, NK cells was significantly higher than that of disease progression group(P <0.05), Treg cell levels were significantly lower than the progress of the group(P <0.05).Conclusion: Various immune parameters in patients with advanced cancer decreased immune function. The immune function of patients after CIK cell therapy could be significantly improved. This improvement in about 30 days after treatment, peaked at about 60 days after treatment and began to decline. CIK combined radiotherapy and chemotherapy can prolong CIK therapy’s improvement of immune function in patients with valid. Remission CIK cell treatment group were significantly better improved in immune function in disease progression group.